Actively Recruiting
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Led by Iovance Biotherapeutics, Inc. · Updated on 2026-04-15
170
Participants Needed
91
Research Sites
551 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
CONDITIONS
Official Title
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who are over 70 years of age may be allowed to enroll after discussion with the Medical Monitor.
- Have historically or pathologically confirmed diagnosis of metastatic Stage IV NSCLC without EGFR, ALK, or ROS1 genomic alterations.
- For patients who have actionable mutations (other than EGFR, ALK, or ROS1 genomic alterations), 1 additional line of therapy with the appropriate health authority approved targeted therapy is required.
- Patients must have documented radiographic disease progression on or after the first-line therapy, including concurrent or sequential ICI and platinum-based chemotherapy �b1 bevacizumab. No more than 1 prior line is allowed if ICI and platinum-based chemotherapy were administered concurrently and no more than 2 prior lines are allowed for sequential administration of platinum-based chemotherapy and ICI as 2 separate lines.
- LN-145 manufacture is allowed for patients who have residual resectable disease after completion of the platinum-based chemotherapy component of the front-line ICI and platinum-based chemotherapy combination and meet all eligibility criteria except documented disease progression. These patients must intend to receive TIL therapy after disease progression
- Prior systemic therapy in the adjuvant or neoadjuvant setting, or as part of definitive chemoradiotherapy, will count as a line of therapy if the patient had disease progression during or within 12 months after the completion of such therapy.
- At least 1 resectable lesion for TIL production and at least one remaining measurable lesion, as defined by RECIST v1.1
- Have adequate organ function
- LVEF > 45%, NYHA Class 1
- Have adequate pulmonary function
- ECOG performance status of 0 or 1
- Patients of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and up to 12 months after all protocol-related therapy
You will not qualify if you...
- Patients who have EGFR, ALK or ROS1 driver mutations
- Patients who have symptomatic, untreated brain metastases.
- Patients who have had allogeneic organ transplant or prior cell therapy within the past 20 years
- Patients who have any form of primary immunodeficiency
- Patients who are on systemic steroid therapy �b9 10 mg/day of prednisone or equivalent.
- Patients who have received a live or attenuated vaccination within 28 days prior to the start of treatment
- Patients who have had another primary malignancy within the previous 3 years
- Participation in another interventional clinical study within 21 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 91 locations
1
Banner Health MD Anderson
Gilbert, Arizona, United States, 85234
Actively Recruiting
2
City of Hope
Duarte, California, United States, 91010
Withdrawn
3
UC San Diego Moores Cancer Center
La Jolla, California, United States, 92037
Withdrawn
4
University of Southern California
Los Angeles, California, United States, 90033
Withdrawn
5
Christiana Care Health System
Newark, Delaware, United States, 19713
Withdrawn
6
University of Florida Health Cancer Center
Gainesville, Florida, United States, 32610
Withdrawn
7
Sylvester Comprehensive Cancer Center
Miami, Florida, United States, 33136
Actively Recruiting
8
AdventHealth Cancer Institute
Orlando, Florida, United States, 32804
Withdrawn
9
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States, 33612
Actively Recruiting
10
Augusta University
Augusta, Georgia, United States, 30912
Actively Recruiting
11
Rush University Medical Center
Chicago, Illinois, United States, 60612
Withdrawn
12
University of Illinois Hospital & Health Sciences System
Chicago, Illinois, United States, 60612
Withdrawn
13
Advocate Aurora Health
Park Ridge, Illinois, United States, 60068
Actively Recruiting
14
University of Kentucky-Markey Cancer Center
Lexington, Kentucky, United States, 40536
Actively Recruiting
15
University of Louisville
Louisville, Kentucky, United States, 40202
Actively Recruiting
16
University of Maryland
Baltimore, Maryland, United States, 21201
Actively Recruiting
17
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Withdrawn
18
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
Actively Recruiting
19
Henry Ford Health System
Detroit, Michigan, United States, 48202
Withdrawn
20
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
21
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
Actively Recruiting
22
MD Anderson Cooper
Camden, New Jersey, United States, 08103
Withdrawn
23
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
Withdrawn
24
New York University Langone Medical Center
New York, New York, United States, 10016
Actively Recruiting
25
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Withdrawn
26
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
27
University of Rochester Medical Center
Rochester, New York, United States, 14642
Withdrawn
28
University of North Carolina
Chapel Hill, North Carolina, United States, 27514
Actively Recruiting
29
Novant Health - Charlotte
Charlotte, North Carolina, United States, 28204
Withdrawn
30
Novant Health - Winston-Salem
Winston-Salem, North Carolina, United States, 27103
Actively Recruiting
31
Atrium Health Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157
Withdrawn
32
Sanford Roger Maris Cancer Center
Fargo, North Dakota, United States, 58102
Actively Recruiting
33
University of Cincinnati Medical Center
Cincinnati, Ohio, United States, 45219
Actively Recruiting
34
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
Actively Recruiting
35
University of Oklahoma
Oklahoma City, Oklahoma, United States, 73104
Withdrawn
36
Oregon Health and Science University
Portland, Oregon, United States, 97239
Actively Recruiting
37
Allegheny General Hospital
Natrona Heights, Pennsylvania, United States, 15065
Actively Recruiting
38
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Withdrawn
39
Sanford Cancer Center
Sioux Falls, South Dakota, United States, 57102
Actively Recruiting
40
Avera Medical Group Cancer Institute
Sioux Falls, South Dakota, United States, 57105
Withdrawn
41
University of Tennessee Medical Center
Knoxville, Tennessee, United States, 37920
Actively Recruiting
42
Baptist Cancer Center
Memphis, Tennessee, United States, 38120
Actively Recruiting
43
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States, 75246
Withdrawn
44
Houston Methodist
Houston, Texas, United States, 77030
Withdrawn
45
VCU Medical Center (Virginia Commonwealth University)
Richmond, Virginia, United States, 23298
Actively Recruiting
46
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109
Actively Recruiting
47
St. Vincent's Hospital
Darlinghurst, New South Wales, Australia, 2010
Actively Recruiting
48
Westmead Hospital
Westmead, New South Wales, Australia, 2145
Actively Recruiting
49
Hollywood Private Hospital Ramsay
Nedlands, Western Australia, Australia, 6009
Actively Recruiting
50
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Canada, QC H2X 3E4
Actively Recruiting
51
Princess Margaret Cancer Centre
Toronto, Canada, M5G 2C1
Withdrawn
52
Institut Paoli Calmettes
Marseille, France, 13009
Actively Recruiting
53
CHU Nantes
Nantes, France, 44093
Actively Recruiting
54
CHU Nice
Nice, France, 06001
Actively Recruiting
55
Centre Hospitalier Lyon Sud
Pierre-Bénite, France, 69310
Actively Recruiting
56
CHRU de Poitiers La Miletrie
Poitiers, France, 90577
Actively Recruiting
57
Gustave Roussy Cancer Campus
Villejuif, France, 94805
Actively Recruiting
58
Charite- Universitätsklinikum Berlin
Berlin, Germany, 13353
Actively Recruiting
59
Universitätsklinikum Bonn
Bonn, Germany, 53127
Actively Recruiting
60
Universitätsklinikum Carl Gustav Carus, MK I
Dresden, Germany, 01307
Actively Recruiting
61
Universitätsklinikum Mannheim
Mannheim, Germany, 68167
Actively Recruiting
62
Azienda Ospedaliera Universitaria Careggi
Florence, Italy, 50134
Actively Recruiting
63
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Italy, 27100
Actively Recruiting
64
Azienda Ospedaliera Ospedali Riuniti Marche Nord
Pesaro, Italy, 61122
Actively Recruiting
65
IRCCS Fondazione del Piemonte per l'Oncologia
Piemonte, Italy, 10060
Actively Recruiting
66
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands, 1066
Actively Recruiting
67
National Cancer Centre Singapore
Singapore, Singapore, 168583
Actively Recruiting
68
Samsung Medical Center
Seoul, Gangnam-gu, South Korea, 6351
Actively Recruiting
69
Gachon Unversity Gil Medical Center
Incheon, South Korea, 21565
Actively Recruiting
70
Severance Hospital, Yonsei University
Seoul, South Korea, 3722
Actively Recruiting
71
Hospital Universitario A Coruña
A Coruña, Spain, 15006
Actively Recruiting
72
Instituto Oncologico Rosell
Barcelona, Spain, 08028
Actively Recruiting
73
Hospital Clinic de Barcelona
Barcelona, Spain, 08036
Actively Recruiting
74
C.H. Regional Reina Sofia
Córdoba, Spain, 14004
Actively Recruiting
75
Hospital Universitario Ramon y Cajal
Madrid, Spain, 28034
Actively Recruiting
76
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Actively Recruiting
77
Hospital Universitario La Paz
Madrid, Spain, 28046
Actively Recruiting
78
Hospital Universitario Madrid Sanchinarro - Centro Integral Oncologico Clara Campal
Madrid, Spain, 28050
Actively Recruiting
79
Hospital Regional Universitario de Malaga
Málaga, Spain, 29016
Actively Recruiting
80
Clinical Universitaria de Navarra
Pamplona, Spain, 31008
Actively Recruiting
81
Hospital Universitario de Salamanca
Salamanca, Spain, 90577
Actively Recruiting
82
Hospital Universitario Virgen del Rocio
Seville, Spain, 41013
Actively Recruiting
83
Hospital Clinico Universitario de Valencia
Valencia, Spain, 46010
Actively Recruiting
84
Consorcio Hospital General Universitario de Valencia
Valencia, Spain, 46014
Actively Recruiting
85
Centre Hospitalier Universitaire Vaudois Lausanne
Lausanne, Canton of Vaud, Switzerland, 1011
Actively Recruiting
86
University Hospital of Zurich/ Universitätsspital Zürich
Zurich, Switzerland, 8091
Withdrawn
87
Royal Marsden Hospital
Chelsea, England, United Kingdom, SW36JJ
Actively Recruiting
88
Sarah Cannon Research Institute
London, England, United Kingdom, W1G 6AD
Actively Recruiting
89
University College London
London, England, United Kingdom, WC1E 68T
Actively Recruiting
90
The Christie NHS Foundation Trust
Manchester, England, United Kingdom, M10 4BX
Actively Recruiting
91
Guy's Hospital
London, United Kingdom, SE1 9RT
Actively Recruiting
Research Team
I
Iovance Biotherapeutics Study Team lungcelltherapy.com
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here